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Objectives: Moldova is a country where expenditure on pharmaceuticals is already 
very high and exceeds several times the prices in the region. Drugs expenditure 
represents 70% of direct health expenditure of a household and is the main factor 
that reduces the financial protection of health care services. The objective of the 
study was to assess affordability of reimbursement medicines and to evaluate the 
National Health Insurance Company (NHIC) impact on ensuring economic accessibil-
ity. MethOds: To determine the affordability of medicines was used the methodology 
recommended by the World Health Organization. Have been analyzed data concern-
ing price of drugs, the amounts paid by patients and the amounts paid by the NHIC 
for partially reimbursed drugs for 5 years (2008-2012). Was calculated: the median 
price for each drug international common name dependent’s on strength; duration of 
treatment and number of units needed for treatment (for chronic disease); number of 
working days required for a treatment cure depending on minimum wage and aver-
age wage in economy. Available treatment is considered, the cost of which is 1 or less 
than the cost of one working day. Based on these results has been also determined 
the impact of the NHIC. Results: Number of economically accessible reimbursed 
drugs depending on minimum wage was: 2008-24 (42%), 2009-34 (60%), 2010-43 (53%), 
2011-48 (58%), and 2012-71 (86%); depending on average wage in economy: 2008-50 
(87%), 2009-50 (87%), 2010-66 (81%), 2011-73 (88%), and 2012-77(94%). The average num-
ber of working days compensated by NHIC based on the minimum wage: 2008-6.23, 
2009-3.5, 2010-3.7, 2011-2.92, and 2012-1.03; based on average wage in economy: 2008-
0.98, 2009-0.76, 2010-0.75, 2011-0.55, and 2012-0.38. cOnclusiOns: Compensation 
of drugs by NHIC, doesn’t significantly affect the affordability of reimbursement 
medicines. Patients feels no real benefit from NHIC, drugs expenditure within the 
households practically remain unchanged even if it get reimbursed medicines.
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Objectives: To assess the methodological quality of economic evaluations included 
in Belgian reimbursement applications for Class 1 drugs. MethOds: For 19 reim-
bursement applications submitted during 2011 and Spring 2012, a descriptive analy-
sis assessed the methodological quality of the economic evaluation, evaluated the 
assessment of that economic evaluation by the Drug Reimbursement Committee 
and the response to that assessment by the company. Compliance with methodo-
logical guidelines issued by the Belgian Healthcare Knowledge Centre was assessed 
using a detailed checklist of 23 methodological items. The rate of compliance was 
calculated based on the number of economic evaluations for which the item was 
applicable. Results: Economic evaluations tended to comply with guidelines 
regarding perspective, target population, subgroup analyses, comparator, use of 
comparative clinical data and final outcome measures, calculation of costs, incre-
mental analysis, discounting and time horizon. However, more attention needs to 
be paid to the description of limitations of indirect comparisons, the choice of an 
appropriate analytic technique, the expression of unit costs in values for the cur-
rent year, the estimation and valuation of outcomes, the presentation of results of 
sensitivity analyses, and testing the face validity of model inputs and outputs. Also, 
a large variation was observed in the scope and depth of the quality assessment by 
the Drug Reimbursement Committee. cOnclusiOns: Although general guidelines 
exist, pharmaceutical companies and the Drug Reimbursement Committee would 
benefit from the existence of a more detailed checklist of methodological items that 
need to be reported in an economic evaluation.
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Objectives: In the CZ, orphan drugs so-called highly innovative drugs first enter 
a temporary reimbursement period of three years. Having proven their cost-effec-
tiveness they later become permanently reimbursed. The objective of the study 
was to determine how successfully orphan drugs enter the database of reimbursed 
drugs. MethOds: The EMA list of orphan drugs was compared to the Czech data-
base of reimbursed drugs to the date of 1-Jul-2013. For each detected drug the date 
of entering the database was found. In drugs reimbursed after 2008, submissions 
of cost effectiveness analyses were recorded. Although CZ has no willingness to 
pay threshold, interpretation of cost effectiveness analyses results could improve 
the process of HTA of drugs. Results: To the date of 1-Apr-2013 the EMA has 
registered 65 orphan drugs. Out of these, 28 have been assigned a maximum and 
reimbursement price in the CZ. To this date, 27 drugs have not applied for reimburse-
ment price. Starting from 2008, 30 drugs have applied: in 20 products the decision 
is legally effective, in 2 cases only hospital use has been approved, in 7 cases (3 
appeals, 4 unfinished proceedings) the proceedings are still in process and in one 
case the application was withdrawn. In about a third of cases a cost effectiveness 
analysis was submitted and accepted by SUKL. The upper limit of the ICER of the 
submitted analyses exceeds by far the cost-effectiveness level recommended by the 
WHO. cOnclusiOns: The results imply that in almost in all cases the submitted 
applications for maximum and reimbursement price are approved by SUKL. In some 
cases, however, the health insurance companies hinder reimbursement of drugs 
by filing an appeal. However, the assessment of cost effectiveness of drugs should 
be performed at an earlier level – during the administrative proceedings. This calls 
for necessary emphasis on health technology assessment.
PHP131
Pricing And reimBursment of PHArmAceuticAls in irAn
Moradi M.
Corvinus University of Budapest, Budapest, Hungary
age including clinical and health economic data and takes on average more than 
two years. In the UK the process is largely based on three different PCT payment 
and the various NHS value for money mechanisms combined with procurement 
systems. The value-based pricing system might change the current situation. Finally, 
in the US CPT codes are similarly being applied as DRG codes in Germany with 
a different pathway of application. In comparison the health economic evidence 
plays a larger role in the UK, even though (still) not in a systematic manner as for 
pharmaceuticals. The clinical evidence plays an important role in all countries, 
however it was identified that for diagnostic tests the access routes and especially 
the coding process is more dependent on consistency on applicability of existing 
codes and technology argumentation. cOnclusiOns: In the different countries 
the evidence base for market access and reimbursement pathways for diagnostics 
differs significantly. Instead, having a unified approach might ease a value based 
market access argumentation for diagnostics.
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Objectives: Considerations beyond (cost-) effectiveness are increasingly important 
in reimbursement decision-making. We investigated the importance of disease sever-
ity relatively to other decision criteria in drug reimbursement decision-making in four 
European countries. MethOds: The importance of disease severity and its operation-
alization was assessed in Belgium, France, The Netherlands and Sweden. We investi-
gated scientific literature, policy documents, reimbursement reports, and conducted 
three interviews in each country (four in The Netherlands) with policymakers involved 
in drug reimbursement. Results: All interviewees acknowledged that disease sever-
ity is, especially in case of high severity, an important criterion while considering 
a drug’s (cost-) effectiveness. However, its relative importance compared to other 
decision criteria remains implicit in the decision-making process. Although rarity of 
the disease is not a criterion as such, interviewees indicated difficulties in separating 
rarity from severity and the availability of alternative treatments. Only Belgium and 
France explicitly show societal willingness to pay by using reimbursement levels 
depending on the severity of the disease. In Sweden, ‘need and solidarity’ is one 
of the three prioritizing principles. The Netherlands is the only country that quan-
titatively operationalized disease severity using the proportional shortfall method 
and suggesting a cost-effectiveness threshold range depending on disease severity 
(which was never formalised by the minister). Although interviewees acknowledged 
that quantitative information, besides a qualitative description of the disease, may 
provide additional decision information, none of them considered such information 
to be of decisive importance. cOnclusiOns: Disease severity is, especially in case 
of high severity, an important decision criterion in all four countries. However, all 
countries seem to struggle in making its actual role explicit. The operationalization 
differs across countries. While Belgium and France are most explicit by using the 
severity of the disease in setting reimbursement levels, all countries could improve 
transparency of its actual importance relatively to other decision criteria.
PHP127
clinicAl And HeAltH economic evidence reQuirements for oBtAining 
HeAltH insurAnce coverAge for innovAtive medicAl devices in 
germAny
Schwander B.1, Krone F.A.2, Walzer S.3
1AHEAD GmbH, Loerrach, Germany, 2Baden-Wuerttemberg Cooperative State University, Lörrach, 
Germany, 3MArS Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany
Objectives: To evaluate the clinical and health economic evidence requirements 
for obtaining statutory health insurance coverage for innovative medical devices 
(MDs) in Germany. MethOds: We have assessed the requirements for innovative 
MDs in Germany according to the available reimbursement pathways and grouped 
them by the application setting as this had a significant impact on the research 
question. Results: According to the German statutory rules in the inpatient care 
setting (reservation of prohibition; ‘Verbotsvorbehalt’) all innovative MDs can be 
applied once they have received marketing approval for Germany (CE mark) whereas 
a positive voting from the federal joint committee is required before MDs can be 
applied in the outpatient setting (reservation of authorization; ‚Erlaubnisvorbehalt’). 
The reimbursement coverage in the inpatient setting depends on the available cod-
ing and grouping mechanisms that define specific diagnoses related groups and 
their reimbursement value. If this value is not adequate or an adequate coding/
grouping is not possible specific applications can be made, that require no specific 
clinical and health economic evidence; only a detailed (additional) cost estimation 
of the new procedure and a rationale of the innovative character are required. In 
contrast the outpatient reimbursement of the statutory health insurance shows 
very strict requirements as a detailed clinical evidence reporting (e.g. randomized-
controlled trials) and a full health economic evaluation (e.g. cost-effectiveness and 
budget impact assessment) need to be provided for obtaining reimbursement cov-
erage. There are recent political streams that claim that the regulatory and reim-
bursement process of MDs should be adapted comparable to the more restrictive 
regulations for pharmaceuticals which might have a major impact on the evidence 
requirements for the inpatient sector. cOnclusiOns: Currently MDs applied in the 
inpatient setting require no specific evidence whereas strong clinical and health 
economic evidence is required for MDs applied in the outpatient setting.
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